Inge M.C.M. de Kok

2.8k total citations
83 papers, 1.7k citations indexed

About

Inge M.C.M. de Kok is a scholar working on Epidemiology, Oncology and Surgery. According to data from OpenAlex, Inge M.C.M. de Kok has authored 83 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Epidemiology, 57 papers in Oncology and 17 papers in Surgery. Recurrent topics in Inge M.C.M. de Kok's work include Cervical Cancer and HPV Research (60 papers), Global Cancer Incidence and Screening (45 papers) and Colorectal Cancer Screening and Detection (21 papers). Inge M.C.M. de Kok is often cited by papers focused on Cervical Cancer and HPV Research (60 papers), Global Cancer Incidence and Screening (45 papers) and Colorectal Cancer Screening and Detection (21 papers). Inge M.C.M. de Kok collaborates with scholars based in Netherlands, United States and Germany. Inge M.C.M. de Kok's co-authors include Marjolein van Ballegooijen, Folkert J. van Kemenade, Joost van Rosmalen, Marc Arbyn, J. Dik F. Habbema, Steffie K. Naber, Matejka Rebolj, Dik Habbema, Martin L. Brown and Albert G. Siebers and has published in prestigious journals such as Gastroenterology, PLoS ONE and JNCI Journal of the National Cancer Institute.

In The Last Decade

Inge M.C.M. de Kok

76 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Inge M.C.M. de Kok Netherlands 26 1.1k 924 309 161 161 83 1.7k
Raúl Murillo Colombia 25 1.2k 1.0× 1.0k 1.1× 437 1.4× 114 0.7× 85 0.5× 117 2.1k
Rebecca Landy United Kingdom 22 891 0.8× 643 0.7× 281 0.9× 88 0.5× 333 2.1× 64 1.6k
Erin N. Kobetz United States 25 736 0.7× 672 0.7× 129 0.4× 53 0.3× 101 0.6× 105 1.7k
Silvana Luciani United States 19 794 0.7× 621 0.7× 141 0.5× 62 0.4× 79 0.5× 70 1.4k
Pierre PL Martin-Hirsch United Kingdom 17 1.5k 1.4× 553 0.6× 545 1.8× 177 1.1× 363 2.3× 20 1.9k
Alejandra Castañón United Kingdom 23 1.9k 1.7× 994 1.1× 494 1.6× 207 1.3× 556 3.5× 55 2.3k
Gauravi Mishra India 18 724 0.6× 689 0.7× 98 0.3× 48 0.3× 113 0.7× 63 1.5k
Tiffany G. Harris United States 23 656 0.6× 300 0.3× 299 1.0× 78 0.5× 128 0.8× 56 1.7k
Amy E. Pollack United States 16 1.2k 1.0× 635 0.7× 292 0.9× 115 0.7× 140 0.9× 28 1.5k
Diama Bhadra Vale Brazil 14 421 0.4× 597 0.6× 119 0.4× 35 0.2× 113 0.7× 65 1.1k

Countries citing papers authored by Inge M.C.M. de Kok

Since Specialization
Citations

This map shows the geographic impact of Inge M.C.M. de Kok's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Inge M.C.M. de Kok with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Inge M.C.M. de Kok more than expected).

Fields of papers citing papers by Inge M.C.M. de Kok

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Inge M.C.M. de Kok. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Inge M.C.M. de Kok. The network helps show where Inge M.C.M. de Kok may publish in the future.

Co-authorship network of co-authors of Inge M.C.M. de Kok

This figure shows the co-authorship network connecting the top 25 collaborators of Inge M.C.M. de Kok. A scholar is included among the top collaborators of Inge M.C.M. de Kok based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Inge M.C.M. de Kok. Inge M.C.M. de Kok is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kok, Inge M.C.M. de, et al.. (2025). Decreasing participation in Dutch population-based cancer screening programs: Trends from 2018 to 2022. Preventive Medicine. 193. 108257–108257.
2.
Jansen, Erik E. L., et al.. (2025). Should the age range of the Dutch hrHPV‐based cervical cancer screening program be broadened? A modelling study using cohort effects. International Journal of Cancer. 157(4). 627–633. 1 indexed citations
3.
4.
Alarid‐Escudero, Fernando, Marina E. Wolf, Ran Zhao, et al.. (2024). State-level disparities in cervical cancer prevention and outcomes in the United States: a modeling study. JNCI Journal of the National Cancer Institute. 117(4). 737–746.
5.
6.
7.
Brule, Adriaan J. C. van den, et al.. (2024). Perspective of obstetric care‐providers on being involved in cervical cancer screening during antenatal care in the Netherlands. Cancer Medicine. 13(13). e7380–e7380.
8.
Fuady, Ahmad, Didik Setiawan, Irene Man, Inge M.C.M. de Kok, & Iacopo Baussano. (2024). Toward a Framework to Assess the Financial and Economic Burden of Cervical Cancer in Low- and Middle-Income Countries: A Systematic Review. JCO Global Oncology. 10(10). e2400066–e2400066. 6 indexed citations
9.
Wolters, Frank J., et al.. (2023). Projections of costs and quality adjusted life years lost due to dementia from 2020 to 2050: A population‐based microsimulation study. Alzheimer s & Dementia. 19(10). 4532–4541. 6 indexed citations
10.
Wolters, Frank J., et al.. (2023). The impact of modifiable risk factor reduction on future dementia burden: a microsimulation modeling study. Alzheimer s & Dementia. 19(S23). 1 indexed citations
11.
Jansen, Erik E. L., et al.. (2022). Shift in harms and benefits of cervical cancer screening in the era of HPV screening and vaccination: a modelling study. BJOG An International Journal of Obstetrics & Gynaecology. 129(11). 1862–1869. 6 indexed citations
12.
Wolters, Frank J., et al.. (2022). Projected prevalence and incidence of dementia accounting for secular trends and birth cohort effects: a population-based microsimulation study. European Journal of Epidemiology. 37(8). 807–814. 11 indexed citations
13.
Jansen, Erik E. L., et al.. (2022). Rapid elimination of cervical cancer while maintaining the harms and benefits ratio of cervical cancer screening: a modelling study. BMC Medicine. 20(1). 433–433. 9 indexed citations
14.
Castañón, Alejandra, Matejka Rebolj, Emily A. Burger, et al.. (2021). Optimal cervical screening COVID-19 recovery strategies in high-income countries depend on context of current programme organisation. The Lancet Public Health. 1 indexed citations
15.
Melis, René J. F., Rick Quax, Eddy A. van der Zee, et al.. (2020). Mapping the multicausality of Alzheimer’s disease through group model building. GeroScience. 43(2). 829–843. 40 indexed citations
16.
Aitken, Clare A., Heleen M.E. van Agt, Albert G. Siebers, et al.. (2019). Introduction of primary screening using high-risk HPV DNA detection in the Dutch cervical cancer screening programme: a population-based cohort study. BMC Medicine. 17(1). 98 indexed citations
17.
Matthijsse, Suzette M., Steffie K. Naber, Jan A. C. Hontelez, et al.. (2018). The health impact of human papillomavirus vaccination in the situation of primary human papillomavirus screening: A mathematical modeling study. PLoS ONE. 13(9). e0202924–e0202924. 8 indexed citations
18.
Matthijsse, Suzette M., Joost van Rosmalen, Jan A. C. Hontelez, et al.. (2015). The Role of Acquired Immunity in the Spread of Human Papillomavirus (HPV): Explorations with a Microsimulation Model. PLoS ONE. 10(2). e0116618–e0116618. 22 indexed citations
19.
Penning, Corine, Albert G. Siebers, Steffie K. Naber, et al.. (2015). Comparing SurePath, ThinPrep, and conventional cytology as primary test method: SurePath is associated with increased CIN II+ detection rates. Cancer Causes & Control. 27(1). 15–25. 45 indexed citations
20.
Kok, Inge M.C.M. de, Steffie K. Naber, Folkert J. van Kemenade, et al.. (2014). Offering Self-Sampling to Non-Attendees of Organized Primary HPV Screening: When Do Harms Outweigh the Benefits?. Cancer Epidemiology Biomarkers & Prevention. 24(5). 773–782. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Raúl Murillo Breakdown of academic impact, for papers by Rebecca Landy Breakdown of academic impact, for papers by Erin N. Kobetz Breakdown of academic impact, for papers by Silvana Luciani Breakdown of academic impact, for papers by Pierre PL Martin-Hirsch Breakdown of academic impact, for papers by Alejandra Castañón Breakdown of academic impact, for papers by Gauravi Mishra Breakdown of academic impact, for papers by Tiffany G. Harris Breakdown of academic impact, for papers by Amy E. Pollack Breakdown of academic impact, for papers by Diama Bhadra Vale
Rankless by CCL
2026